Compositions for the treatment of cns-related conditions
AssigneeAdamas Pharmaceuticals, Inc.
InventorsGregory T. Went, Timothy J. Fultz, Laurence R. Meyerson
Life of this patent
Estimating the term…
Abstract
The invention provides methods for treating CNS-related conditions with amantadine and donepezil, in which the amantadine is in an extended release form, wherein the extended release amantadine formulation provides a change in plasma concentration as a function of time (dC/dT) that is less than 40% of the dC/dT of the same quantity of an immediate release form of amantadine.
Claims27
1-10. (canceled)
A solid pharmaceutical composition in a unit dosage form for once daily, oral administration comprising:
- a) a first drug selected from the group consisting of memantine and a pharmaceutically acceptable salt thereof in an amount of 22.5 mg to 33.75 mg;
- b) a second drug selected from the group consisting of donepezil and a pharmaceutically acceptable salt thereof in an amount of 1 mg to 10 mg;
- and
- c) at least one excipient that modifies release of said first drug to provide an extended release form of said first drug,
- wherein said pharmaceutical composition provides a ratio of maximum plasma concentration (Cmax) of memantine to average plasma concentration (Cmean) of memantine of about 1.6 to 2.5 wherein Cmax and Cmean are determined over a period from about 1.5 to 12 hours after oral administration of said pharmaceutical composition to a human subject of a single dose human pharmacokinetic study.
A solid pharmaceutical composition in a unit dosage form for once daily, oral administration comprising:
- a) a first drug selected from the group consisting of memantine and a pharmaceutically acceptable salt thereof in an amount of 22.5 mg to 33.75 mg;
- b) a second drug selected from the group consisting of donepezil and a pharmaceutically acceptable salt thereof in an amount of 1 mg to 10 mg;
- and
- c) at least one excipient that modifies release of said first drug to provide an extended release form of said first drug,
- wherein said pharmaceutical composition provides a ratio of a maximum plasma concentration (Cmax) of memantine to average plasma concentration (Cmean) of memantine of about 1.5 to 2.5 wherein Cmax and Cmean are determined over a period from about 2 to 12 hours after oral administration of said pharmaceutical composition to a human subject of a single dose human pharmacokinetic study.
Dependencies are inferred from the claim text.